PFM Health Sciences Leads $175M Series B Financing of Metagenomi
Gunderson Dettmer represented client PFM Health Sciences as it led the $175M Series B financing of Metagenomi, a genetic medicines company with an assortment of next-generation gene-editing tools. The new capital will be used to advance Metagenomi’s in-vivo and ex-vivo gene editing therapeutic programs, expand its manufacturing, automation, and Al infrastructure, and develop the company’s set of next-generation gene-editing tools.
In the announcement of the transaction, partner at PFM Health Sciences Santhosh Palani, Ph.D. said, “We are thrilled to be able to support Metagenomi as they advance their gene-editing programs towards the clinic. Their gene-editing systems hold the potential to have major benefits for patients.” In addition to the new round, Palani is being added to Metagenomi’s Board of Directors.
The Gunderson deal team was led by Bennett Yee and Nate Gray and included Bella Thornton-Clark and Micaela Cervantes. Gina Marek and Phoebe Hung advised on intellectual property-related matters and Mark Foster and Sunny Kim advised on tax-related matters.
PFM Health Sciences